Erratum: Department of Error (The Lancet (2019) 393(10174) (889–898), (S0140673619300364), (10.1016/S0140-6736(19)30036-4));Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

The Lancet

Volumn 393, Issue 10174, 2019, Pages 889-898

  Gaudinski, Martin R ^a   Coates, Emily E ^a   Novik, Laura ^a   Widge, Alicia ^a   Houser, Katherine V ^a   Burch, Eugeania ^a   Holman, LaSonji A ^a   Gordon, Ingelise J ^a   Chen, Grace L ^a   Carter, Cristina ^a   Nason, Martha ^a   Sitar, Sandra ^a   Yamshchikov, Galina ^a   Berkowitz, Nina ^a   Andrews, Charla ^a   Vazquez, Sandra ^a,c   Laurencot, Carolyn ^a   Misasi, John ^a   Arnold, Frank ^a   Carlton, Kevin ^a   Lawlor, Heather ^a   Gall, Jason ^a   Bailer, Robert T ^a   McDermott, Adrian ^a   Capparelli, Edmund ^b   Koup, Richard A ^a   Mascola, John R ^a   Graham, Barney S ^a   Sullivan, Nancy J ^a   Ledgerwood, Julie E ^a   Hendel, Cynthia Starr ^c   Plummer, Sarah H ^c   Costner, Pamela ^c   Saunders, Jamie ^c   Mendoza, Floreliz ^c   Eshun, Aba Mensima ^c   Casazza, Joseph ^c   Ola, Abidemi ^c   Whalen, William ^c   Wang, Xiaolin ^c   Cunningham, Jennifer ^c   Vasilenko, Olga ^c   Boyd, Catina R ^c   Trofymenko, Olga ^c   Burgos Florez, Maria Claudia ^c   Hickman, Somia ^c   Rothwell, Ro Shauna ^c   Pittman, Iris R ^c   Le, Lam Ngan ^c   Larkin, Brenda D ^c   Cox, Josephine H ^c   Apte, Preeti J ^c   Hicks, Renunda T ^c   Trelles Cartagena, Cora ^c   Williams, Pernell V ^c   Requilman, LaShawn ^c   Nguyen, Thuy ^c   Tran, Colin ^c   Conan Cibotti, Michelle ^c   Stein, Judy ^c   Beresnev, Tatiana ^c   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

MAB114; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; EBOLA VACCINE; IMMUNOLOGIC FACTOR; VIRAL PROTEIN;

ADULT; ANTIBODY PRODUCTION; ARTHRALGIA; ARTICLE; CHILL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HUMAN EXPERIMENT; INFUSION RATE; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINE IMMUNOGENICITY; ANIMAL; CLINICAL TRIAL; DOSE RESPONSE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; RHESUS MONKEY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EBOLA VACCINES; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNOLOGIC FACTORS; MACACA MULATTA; MALE; MIDDLE AGED; VIRAL PROTEINS; YOUNG ADULT;

EID: 85061347966     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(20)31195-8     Document Type: Erratum

References (37)

1. Kuhn, JH, Bao, Y, Bavari, S, et al. Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol 158 (2013), 301–311.
2. Sanchez, A, Kiley, MP, Holloway, BP, Auperin, DD, Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res 29 (1993), 215–240.
3. WHO. Ebola virus disease. Feb 12, 2018, World Health Organization, Geneva https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease. (Accessed 21 December 2018)
4. Geisbert, TW, Jahrling, PB, Exotic emerging viral diseases: progress and challenges. Nat Med 10:suppl (2004), S110–S121.
5. Meslin, FX, Global aspects of emerging and potential zoonoses: a WHO perspective. Emerg Infect Dis 3 (1997), 223–228.
6. Okware, SI, Omaswa, FG, Zaramba, S, et al. An outbreak of Ebola in Uganda. Trop Med Int Health 7 (2002), 1068–1075.
7. Bausch, DG, Towner, JS, Dowell, SF, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 196:suppl 2 (2007), S142–S147.
8. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 56 (1978), 271–293.
9. WHO. Situation report: Ebola virus disease. June 10, 2016, World Health Organization, Geneva http://apps.who.int/iris/bitstream/handle/10665/208883/ebolasitrep_10Jun2016_eng.pdf?sequence=1. (Accessed 21 December 2018)
10. WHO. Ebola situation report: Democratic Republic of the Congo. Geneva: World Health Organization. www.who.int/ebola/situation-reports/drc-2018/en/. (Accessed 17 January 2019)
11. WHO. Ebola virus disease – Democratic Republic of the Congo. Aug 4, 2018, World Health Organization, Geneva http://www.who.int/csr/don/4-august-2018-ebola-drc/en/. (Accessed 21 December 2018)
12. Mupapa, K, Massamba, M, Kibadi, K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 179:suppl 1 (1999), S18–S23.
13. van Griensven, J, Edwards, T, de Lamballerie, X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 374 (2016), 33–42.
14. Sahr, F, Ansumana, R, Massaquoi, TA, et al. Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. J Infect 74 (2017), 302–309.
15. Jahrling, PB, Geisbert, JB, Swearengen, JR, Larsen, T, Geisbert, TW, Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 196:suppl 2 (2007), S400–S403.
16. Jahrling, PB, Geisbert, TW, Jaax, NK, Hanes, MA, Ksiazek, TG, Peters, CJ, Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989–1990 U.S. epizootic. Arch Virol Suppl 11 (1996), 115–134.
17. Dye, JM, Herbert, AS, Kuehne, AI, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA 109 (2012), 5034–5039.
18. Sullivan, NJ, Hensley, L, Asiedu, C, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 17 (2011), 1128–1131.
19. Qiu, X, Wong, G, Audet, J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514 (2014), 47–53.
20. Pascal, KE, Dudgeon, D, Trefry, JC, et al. Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in non-human primates. J Infect Dis 218:suppl 5 (2018), s612–s626.
21. Murphy, AJ, Macdonald, LE, Stevens, S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA 111 (2014), 5153–5158.
22. Sivapalasingam, S, Kamal, M, Slim, R, et al. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study. Lancet Infect Dis 18 (2018), 884–893.
23. The PREVAIL II Writing Group. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med 375 (2016), 1448–1456.
24. Ploquin, A, Zhou, Y, Sullivan, NJ, Ebola immunity: gaining a winning position in lightning chess. J Immunol 201 (2018), 833–842.
25. Misasi, J, Gilman, MS, Kanekiyo, M, et al. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 351 (2016), 1343–1346.
26. Côte, M, Misasi, J, Ren, T, et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477 (2011), 344–348.
27. Misasi, J, Chandran, K, Yang, JY, et al. Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences. J Virol 86 (2012), 3284–3292.
28. Carette, JE, Raaben, M, Wong, AC, et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477 (2011), 340–343.
29. Misasi, J, Sullivan, NJ, Camouflage and misdirection: the full-on assault of ebola virus disease. Cell 159 (2014), 477–486.
30. Corti, D, Misasi, J, Mulangu, S, et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351 (2016), 1339–1342.
31. Kuhn, JH, Radoshitzky, SR, Guth, AC, et al. Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem 281 (2006), 15951–15958.
32. Division of AIDS. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, version 2.1. March, 2017, US National Institute of Allergy and Infectious Diseases, US National Institutes of Health, US Department of Health and Human Services.
33. Gaudinski, MR, Coates, EE, Houser, KV, et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults. PLoS Med, 15, 2018, e1002493.
34. Qiu, X, Audet, J, Lv, M, et al. Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Sci Transl Med, 8, 2016, 329ra33.
35. Qiu, X, Audet, J, Wong, G, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med, 4, 2012, 138ra81.
36. Davidson, E, Bryan, C, Fong, RH, et al. Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies. J Virol 89 (2015), 10982–10992.
37. Pallesen, J, Murin, CD, de Val, N, et al. Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nat Microbiol, 1, 2016, 16128.